Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Denali Therapeutics (DNLI) Net Margin (2018 - 2023)

Historic Net Margin for Denali Therapeutics (DNLI) over the last 6 years, with Q3 2023 value amounting to 7841.59%.

  • Denali Therapeutics' Net Margin fell 49391200.0% to 7841.59% in Q3 2023 from the same period last year, while for Jun 2024 it was 33121.86%, marking a year-over-year decrease of 330844500.0%. This contributed to the annual value of 43.94% for FY2023, which is 2566200.0% up from last year.
  • Per Denali Therapeutics' latest filing, its Net Margin stood at 7841.59% for Q3 2023, which was down 49391200.0% from 62.35% recorded in Q2 2023.
  • Over the past 5 years, Denali Therapeutics' Net Margin peaked at 77.3% during Q4 2020, and registered a low of 7841.59% during Q3 2023.
  • Moreover, its 5-year median value for Net Margin was 884.02% (2021), whereas its average is 1192.12%.
  • In the last 5 years, Denali Therapeutics' Net Margin skyrocketed by 30895700bps in 2019 and then plummeted by -49391200bps in 2023.
  • Denali Therapeutics' Net Margin (Quarter) stood at 1156.36% in 2019, then soared by 107bps to 77.3% in 2020, then crashed by -878bps to 601.41% in 2021, then plummeted by -60bps to 959.62% in 2022, then plummeted by -717bps to 7841.59% in 2023.
  • Its Net Margin was 7841.59% in Q3 2023, compared to 62.35% in Q2 2023 and 312.4% in Q1 2023.